TheStreet upgraded shares of Lantheus (NASDAQ:LNTH) from a d rating to a c- rating in a research report report published on Monday.

LNTH has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Lantheus from a buy rating to a hold rating in a research report on Tuesday, January 30th. BidaskClub raised shares of Lantheus from a hold rating to a buy rating in a research report on Wednesday, December 27th. Finally, ValuEngine raised shares of Lantheus from a hold rating to a buy rating in a research report on Saturday, February 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $24.75.

How to Become a New Pot Stock Millionaire

Shares of Lantheus stock opened at $16.15 on Monday. The company has a debt-to-equity ratio of 11.40, a current ratio of 3.16 and a quick ratio of 2.60. Lantheus has a 1 year low of $10.65 and a 1 year high of $24.45. The company has a market cap of $588.73, a P/E ratio of 5.13, a price-to-earnings-growth ratio of 1.24 and a beta of 1.56.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Monday, February 26th. The medical equipment provider reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.08). Lantheus had a negative return on equity of 68.13% and a net margin of 37.23%. The company had revenue of $81.24 million during the quarter, compared to the consensus estimate of $78.57 million. During the same period last year, the firm posted $0.18 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. equities analysts expect that Lantheus will post 1.04 earnings per share for the current year.

In related news, insider Michael P. Duffy sold 21,655 shares of Lantheus stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $22.40, for a total transaction of $485,072.00. Following the transaction, the insider now owns 156,784 shares in the company, valued at approximately $3,511,961.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Timothy G. Healey sold 3,696 shares of Lantheus stock in a transaction on Monday, February 26th. The shares were sold at an average price of $19.58, for a total transaction of $72,367.68. Following the transaction, the senior vice president now owns 64,582 shares in the company, valued at approximately $1,264,515.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,709 shares of company stock valued at $839,135. Insiders own 2.30% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Lantheus by 13.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 32,861 shares of the medical equipment provider’s stock valued at $672,000 after buying an additional 3,841 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Lantheus during the 4th quarter valued at $267,000. Cornerstone Capital Management Holdings LLC. lifted its stake in shares of Lantheus by 95.4% during the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 186,800 shares of the medical equipment provider’s stock valued at $3,819,000 after buying an additional 91,200 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Lantheus by 24.8% during the 4th quarter. Teachers Advisors LLC now owns 646,336 shares of the medical equipment provider’s stock valued at $13,218,000 after buying an additional 128,533 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of Lantheus by 4.8% during the 4th quarter. Two Sigma Advisers LP now owns 91,400 shares of the medical equipment provider’s stock valued at $1,869,000 after buying an additional 4,200 shares in the last quarter. Institutional investors own 90.47% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2018/03/21/lantheus-lnth-rating-increased-to-c-at-thestreet.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.